Increased Cardiovascular Risk With Lorlatinib in Patients With ALK‐Mutated Lung Cancer: A Real‐World Comparative Study
Journal of the American Heart Association · 2025
DOI: 10.1161/jaha.125.043620 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Chien-Yu Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, College of Medicine National Cheng Kung University Tainan Taiwan. Hauptthemen laut MEDLINE: Lung Neoplasms, Anaplastic Lymphoma Kinase, Aminopyridines, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
The discovery of driver mutations has transformed advanced non–small cell lung cancer treatment, with ALK (anaplastic lymphoma kinase)–rearranged patients achieving longest overall survival. However, the risk of cancer therapy–related cardiovascular diseases (CTRCVDs) is underrecognized, particularly comparing second‐generation ALK–tyrosine kinase inhibitors alectinib and brigatinib to the third‐generation tyrosine kinase inhibitor lorlatinib, which offers the longest progression‐free survival. We aimed to compare CTRCVDs risks among patients with lung cancer receiving ALK‐tyrosine kinase inhibitor, assess incidence trends, and identify clinical risk factors associated with ALK‐tyrosine kinase inhibitor‐related CTRCVDs.
Methods
This retrospective cohort study of 946 848 adults with lung cancer (2010–2024) using TriNetX compared CTRCVDs risk in ALK‐mutated patients treated with lorlatinib versus brigatinib/alectinib. After excluding ROS1‐mutated cases and 1:1 propensity score matching, 744 patients per group were analyzed. CTRCVDs, defined as myocardial infarction, stroke, arterial embolism, or heart failure, were evaluated with Kaplan–Meier analysis and Cox proportional hazards models over 2 years.
Results
Lorlatinib treatment was associated with a significantly increased risk of CTRCVDs (hazard ratio [HR], 3.00 [95% CI, 1.65–5.45]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, College of Medicine National Cheng Kung University Tainan Taiwan.
- Department of Internal Medicine National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan.
- Division of Medical Oncology, Department of Internal Medicine The Ohio State University Comprehensive Cancer Center Columbus OH.
- Department of Psychiatry Chi Mei Medical Center Tainan Taiwan.
- Department of Medical Imaging National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan.
- Institute of Molecular Medicine, College of Medicine National Cheng Kung University Tainan 701 Taiwan.
ORCID-Profile: Chien-Yu Lin, Po-Lan Su, Chin-Wei Kuo, Ting-Hui Liu, Jen Yang, Chien-Chung Lin, Sheng-Hsiang Lin
Zitieren
APA
Lin, C. Y., Su, P. L., Kuo, C. W., Tsai, I. L., Liu, T. H., Yang, J., Lin, C. C., & Lin, S. H. (2025). Increased Cardiovascular Risk With Lorlatinib in Patients With ALK‐Mutated Lung Cancer: A Real‐World Comparative Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.043620
Vancouver
Lin CY, Su PL, Kuo CW, Tsai IL, Liu TH, Yang J, et al. Increased Cardiovascular Risk With Lorlatinib in Patients With ALK‐Mutated Lung Cancer: A Real‐World Comparative Study. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.043620
BibTeX
@article{Lin2025,
author = {Lin, Chien-Yu and Su, Po-Lan and Kuo, Chin-Wei and Tsai, I-Lin and Liu, Ting-Hui and Yang, Jen and Lin, Chien-Chung and Lin, Sheng-Hsiang},
title = {Increased Cardiovascular Risk With Lorlatinib in Patients With ALK‐Mutated Lung Cancer: A Real‐World Comparative Study},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.125.043620}
}
EUVIMED